文献速递妇科

基于人乳头瘤病毒状态的宫颈癌基因组特征分析

Genomic characterization of cervical cancer based on human papillomavirus status.
PubMed 文献 · Gynecol Oncol · 2018-12-20

本研究基于TCGA公共数据比较HPV阳性与HPV阴性宫颈癌的基因组特征,分析299例患者临床信息,鉴定差异表达基因并进行功能注释、通路映射、生存分析和体细胞突变图谱比较,进一步推断对放化疗的应答可能性。

要点

  • HPV阴性肿瘤多见于年龄较大患者,常为腺癌或腺鳞癌,两组总生存无显著差异。
  • ANKRD7、SERPINB3、EMX2、MEI1、RNF212等基因表达在HPV阳性与阴性肿瘤间存在差异且与预后相关。
  • TP53、ARID5B、ARID1A、CTNNB1和PTEN在两组间突变存在显著差异。

核心结论

  • 这些潜在生物标志物可能为进一步个体化治疗决策、改善HPV阴性宫颈癌患者生存提供见解。

研究设计与样本

  • 基于TCGA公共数据,首先收集并分析299例宫颈癌患者的临床信息,随后鉴定差异表达基因并进行下游分析以基于HPV状态表征该肿瘤,包括功能注释、通路映射、生存分析和比较体细胞突变图谱,并进一步推断对放疗和化疗等传统治疗的应答可能性。

主要发现

  • HPV阴性肿瘤可能发生于较年长年龄,且常为腺癌或腺鳞癌,HPV阳性与HPV阴性肿瘤之间总生存无显著差异。
  • HPV阳性与HPV阴性肿瘤的基因表达谱存在差异,尤其在ANKRD7、SERPINB3、EMX2、MEI1、RNF212、RP11-13 K12.5、RP11-325F22.2和ZFR2,这些基因与宫颈癌预后显著相关。
  • TP53、ARID5B、ARID1A、CTNNB1和PTEN在HPV阳性与HPV阴性肿瘤之间突变存在显著差异。
  • 放疗分析结果显示CDO1、PCDHB2和MYOD1在两个亚组之间存在差异。
  • RP11-299 L17.3、SLC14A2、FGF18和OASL在两组之间对顺铂表现出不同的药物敏感性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: It is uncommon for cervical cancer patients to be diagnosed without a human papillomavirus (HPV) infection. As prophylactic vaccines against high-risk HPV types are an ineffective preventive measure for these patients it is essential to identify differential biomarkers that may be associated with detection, prognosis and novel targeted therapies. The objective of this study was to compare the two entities, HPV+ and HPV- cervical cancers, based on TCGA public data. METHODS: We collected and analyzed clinical information of 299 cervical cancer patients as the first step, then identified differential expressed genes and conducted downstream analyses to characterize this tumor based on HPV status, including functional annotation, pathway mapping, survival analysis and comparative somatic mutation landscapes. We further inferred the likelihood of responding to traditional treatment including radiotherapy and chemotherapy. RESULTS: It was found that HPV- tumors were likely to occur at an older age and were often adenocarcinomas or adenosquamous carcinomas, and there was no significant overall survival difference between HPV+ vs. HPV- tumors. Gene expression profiles of HPV+ and HPV- tumors differed especially in ANKRD7, SERPINB3, EMX2, MEI1, RNF212, RP11-13 K12.5, RP11-325F22.2 and ZFR2 which were significantly relevant to cervical cancer prognosis. TP53, ARID5B, ARID1A, CTNNB1 and PTEN were significantly differentially mutated between HPV+ and HPV- tumors. Results of radiotherapy analyses demonstrated that CDO1, PCDHB2 and MYOD1 were different between the two subsets. In addition, RP11-299 L17.3, SLC14A2, FGF18 and OASL represented different drug-sensitivity to cisplatin between both. CONCLUSIONS: These potential biomarkers may offer insights to further personalize therapeutic decision-making to improve survival in HPV- cervical cancer patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang L, Jiang Y, Lu X, et al. Genomic characterization of cervical cancer based on human papillomavirus status. Gynecol Oncol. 2018. PMID: 30581036. doi:10.1016/j.ygyno.2018.12.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。